Review Article
The Molecular Biology of Soft-Tissue Sarcomas and Current Trends in Therapy
Table 5
Current Anti-IGF treatment of sarcomas.
| | Monoclonal antibodies | Human trials | Disease control rate (CR, PR, and SD) | Comments |
| | Figitumumab CP-751, 871 | ES/STS | 10/28 (35%) | Anti-IGF-IR | | Cixutumumab | STS | 22/37 (59%) | Liposarcomas; block hybrid receptors | | Robatumumab SCH 717454 | Preclinical | OS, RMS | Anti-IGF-IR | | Ganitumab AMG479 | ES | 2/15 (13%) | | | RI 507 | ES | 18/125 (14.4%) | No SD included |
| | TK inhibitors | Status | Target disease | |
| | NVP-AEW541 | Preclinical | ES/STS/GIST | Synergy with chemoRx | | NVP-ADW 742 | Preclinical | ES | Synergy with imatinib | | BMS-536924 | Preclinical | STS | ATP-competitive IGF-IR |
| | Others | Status | Target disease | |
| | Nordihydroguaiaretic acid (NDGA) | Preclinical | STS | Disrupts IGF-1R; blocks HER-2 |
|
|
